Aphali Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 30-06-2024
- Paid Up Capital ₹ 2.22 M
as on 30-06-2024
- Company Age 91 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -7.50%
(FY 2017)
- Profit 9.57%
(FY 2017)
- Ebitda -1065.74%
(FY 2017)
- Net Worth -7.99%
(FY 2017)
- Total Assets -10.88%
(FY 2017)
About Aphali Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.22 M, as per Ministry of Corporate Affairs (MCA) records.
Seema Kasat, Aniruddha Kasat, Siddharth Kasat, and One other member serve as directors at the Company.
- CIN/LLPIN
U27239MH1933PLC002027
- Company No.
002027
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Oct 1933
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aphali Pharmaceuticals Limited offer?
Aphali Pharmaceuticals Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets.
Who are the key members and board of directors at Aphali Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shyam Kasat  | Managing Director | 24-Apr-1979 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Siddharth Kasat | Director | 10-Jul-2023 | Current |
| Seema Kasat | Director | 30-Jan-1996 | Current |
| Aniruddha Kasat | Director | 10-Mar-2016 | Current |
Financial Performance of Aphali Pharmaceuticals.
Aphali Pharmaceuticals Limited, for the financial year ended 2017, experienced Minor drop in revenue, with a 7.5% decrease. The company also saw a slight improvement in profitability, with a 9.57% increase in profit. The company's net worth dipped by a decrease of 7.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aphali Pharmaceuticals?
In 2017, Aphali Pharmaceuticals had a promoter holding of 48.24% and a public holding of 51.76%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tarujyot Investments LimitedActive 40 years 3 months
Siddharth Kasat and Shyam Kasat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aphali Pharmaceuticals?
Aphali Pharmaceuticals has a workforce of 17 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aphali Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aphali Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
